[HTML][HTML] Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
MF Fransen, M Schoonderwoerd, P Knopf… - JCI insight, 2018 - ncbi.nlm.nih.gov
Abstract PD-1/PD-L1 checkpoint therapy for cancer is commonly considered to act by
reactivating T cells in the tumor microenvironment. Here, we present data from 2 mouse …
reactivating T cells in the tumor microenvironment. Here, we present data from 2 mouse …
[HTML][HTML] A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
IN Pardieck, TC van der Sluis… - Nature …, 2022 - nature.com
Understanding the mechanisms and impact of booster vaccinations are essential in the
design and delivery of vaccination programs. Here we show that a three dose regimen of a …
design and delivery of vaccination programs. Here we show that a three dose regimen of a …
Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates
GG Zom, S Khan, CM Britten, V Sommandas… - Cancer immunology …, 2014 - AACR
Chemical conjugates comprising synthetic Toll-like receptor ligands (TLR-L) covalently
bound to antigenic synthetic long peptides (SLP) are attractive vaccine modalities, which …
bound to antigenic synthetic long peptides (SLP) are attractive vaccine modalities, which …
Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines
MG Carstens, MGM Camps, M Henriksen-Lacey… - Vaccine, 2011 - Elsevier
The formulation of plasmid DNA (pDNA) in cationic liposomes is a promising strategy to
improve the potency of DNA vaccines. In this respect, physicochemical parameters such as …
improve the potency of DNA vaccines. In this respect, physicochemical parameters such as …
[HTML][HTML] Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication
GG Zom, MM Willems, S Khan, TC van der Sluis… - … for immunotherapy of …, 2018 - Springer
Abstract Background Ligands for the Toll-like receptor (TLR) family can induce activation of
cells of the innate immune system and are widely studied for their potential to enhance …
cells of the innate immune system and are widely studied for their potential to enhance …
Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
The murine MC-38 colorectal cancer model is a commonly used model for cancer with high
mutational burden, which is sensitive for immune checkpoint immunotherapy. We set out to …
mutational burden, which is sensitive for immune checkpoint immunotherapy. We set out to …
Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cells
The genetic circuits that allow cancer cells to evade immune killing via epithelial
mesenchymal plasticity remain poorly understood. Here, we showed that mesenchymal-like …
mesenchymal plasticity remain poorly understood. Here, we showed that mesenchymal-like …
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells
FcγR ligation by Ag–Ab immune complexes (IC) not only mediates effective Ag uptake, but
also strongly initiates dendritic cell (DC) maturation, a requirement for effective T cell …
also strongly initiates dendritic cell (DC) maturation, a requirement for effective T cell …
[HTML][HTML] Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles
CG Da Silva, MGM Camps, TMWY Li, L Zerrillo… - Theranostics, 2019 - ncbi.nlm.nih.gov
Chemoimmunotherapy is an emerging combinatorial modality for the treatment of cancers
resistant to common first-line therapies, such as chemotherapy and checkpoint blockade …
resistant to common first-line therapies, such as chemotherapy and checkpoint blockade …
Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer
Therapeutic cancer drug efficacy can be limited by insufficient tumor penetration, rapid
clearance, systemic toxicity and (acquired) drug resistance. The poor therapeutic index due …
clearance, systemic toxicity and (acquired) drug resistance. The poor therapeutic index due …